Clinical trial
A Randomized, Double-blind, Parallel Group, Proof of Concept Study of YM178 in Comparison With Placebo and Tolterodine in Patients With Symptomatic Overactive Bladder
NCT01604928 is registered in ClinicalTrials.gov with Astellas Pharma Europe B.V. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Parallel Group, Proof of Concept Study of YM178 in Comparison With Placebo and Tolterodine in Patients With Symptomatic Overactive Bladder
- Lead sponsor
- Astellas Pharma Europe B.V.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 5, 2004
- Completion date
- January 25, 2005
- Enrollment
- 260 (actual)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.